PainReform (NASDAQ:PRFX) Stock Crosses Above 50-Day Moving Average – Should You Sell?

PainReform Ltd. (NASDAQ:PRFX) shares passed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $0.87 and traded as high as $0.8870. PainReform shares last traded at $0.8709, with a volume of 72,346 shares trading hands.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a research report on Thursday, October 15th. Wall Street Zen upgraded PainReform to a “sell” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

PainReform Trading Up 14.8%

The stock has a market cap of $757,683.00, a P/E ratio of -0.00 and a beta of 1.16. The stock has a 50 day simple moving average of $0.87 and a 200 day simple moving average of $1.76.

PainReform (NASDAQ:PRFX) last released its earnings results on Thursday, September 3rd. The company reported ($1.13) earnings per share for the quarter. The firm had revenue of $0.01 million for the quarter.

About PainReform

PainReform Ltd. (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for acute post-operative pain. The company’s work is aimed at addressing pain experienced after surgical procedures and reducing reliance on conventional short-acting analgesics.

PainReform’s lead product candidate, PRF-110, is an extended-release formulation of ropivacaine, a local anesthetic. Designed for administration at the surgical site, PRF-110 is intended to provide prolonged pain relief during the days following surgery.